Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): I. Drugs in preclinical and early clinical development

Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy

Yu, F. H., Mantegazza, M., Westenbroek, R. E., Robbins, C. A., Kalume, F., Burton, K. A., Spain, W. J., McKnight, G. S., Scheuer, T., & Catterall, W. A. (2006) · Nature Neuroscience · doi:10.1038/nn1754 · Cited by 1,173 · see citing works

Epilepsy

Devinsky, O., Vezzani, A., O'Brien, T. J., Jetté, N., Scheffer, I. E., de Curtis, M., & Perucca, P. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.24 · Cited by 967 · see citing works

Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders

Rupprecht, R., Papadopoulos, V., Rammes, G., Baghai, T. C., Fan, J., Akula, N., Groyer, G., Adams, D., & Schumacher, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3295 · Cited by 930 · see citing works

Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy

Vezzani, A., Balosso, S., & Ravizza, T. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0217-x · Cited by 907 · see citing works

Distinct contributions of Nav1.6 and Nav1.2 in action potential initiation and backpropagation

Hu, W., Tian, C., Li, T., Yang, M., Hou, H., & Shu, Y. (2009) · Nature Neuroscience · doi:10.1038/nn.2359 · Cited by 706 · see citing works

The natural history of epilepsy in tuberous sclerosis complex

Chu, C. J., Major, P., Camposano, S. E., Muzykewicz, D. A., & Thiele, E. A. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02474.x · Cited by 638 · see citing works

Aberrant hippocampal neurogenesis contributes to epilepsy and associated cognitive decline

Cho, K.-O., Lybrand, Z. R., Ito, N., Brulet, R., Tafacory, F., Zhang, L., Good, L., Ure, K., Kernie, S. G., Birnbaum, S. G., et al. (2015) · Nature Communications · doi:10.1038/ncomms7606 · Cited by 451 · see citing works

The mechanism of action of retigabine (ezogabine), a first‐in‐class K + channel opener for the treatment of epilepsy

Gunthorpe, M. J., Large, C. H., & Sankar, R. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2011.03365.x · Cited by 319 · see citing works

CB2 Cannabinoid Receptors as a Therapeutic Target—What Does the Future Hold?

Dhopeshwarkar, A., & Mackie, K. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.094649 · Cited by 254 · see citing works

KCNQ2 encephalopathy

Millichap, J. G., Park, K., Tsuchida, T. N., Ben‐Zeev, B., Carmant, L., Flamini, R. J., Joshi, N., Levisohn, P. M., Marsh, E. D., Nangia, S., et al. (2016) · Neurology Genetics · doi:10.1212/nxg.0000000000000096 · Cited by 241 · see citing works

From genotype to phenotype in Dravet disease

Gataullina, S., & Dulac, O. (2016) · Seizure · doi:10.1016/j.seizure.2016.10.014 · Cited by 179 · see citing works

Orphan GPR110 (ADGRF1) targeted by N-docosahexaenoylethanolamine in development of neurons and cognitive function

Lee, J.-W., Huang, B. X., Kwon, H., Rashid, M. A., Kharebava, G., Desai, A., Patnaik, S., Marugán, J., & Kim, H. (2016) · Nature Communications · doi:10.1038/ncomms13123 · Cited by 162 · see citing works

CANnabinoid Receptor Type 2 Activation Induces a Microglial Anti-Inflammatory Phenotype and Reduces Migration via MKP Induction and ERK Dephosphorylation

Romero-Sandoval, E. A., Horvath, R. J., Landry, R. P., & DeLeo, J. A. (2009) · Molecular Pain · doi:10.1186/1744-8069-5-25 · Cited by 159 · see citing works

Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in preclinical and early clinical development

Bialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2020) · Epilepsia · doi:10.1111/epi.16725 · Cited by 149 · see citing works

SCN8A encephalopathy: Research progress and prospects

Meisler, M. H., Helman, G., Hammer, M. F., Fureman, B. E., Gaillard, W. D., Goldin, A. L., Hirose, S., Ishii, A., Kroner, B. L., Lossin, C., et al. (2016) · Epilepsia · doi:10.1111/epi.13422 · Cited by 135 · see citing works

Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development

Bialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2018) · Epilepsia · doi:10.1111/epi.14557 · Cited by 130 · see citing works

Spinal Cannabinoid Receptor Type 2 Activation Reduces Hypersensitivity and Spinal Cord Glial Activation after Paw Incision

Romero-Sandoval, A. E., & Eisenach, J. C. (2007) · Anesthesiology · doi:10.1097/01.anes.0000264765.33673.6c · Cited by 122 · see citing works

N-Docosahexaenoylethanolamine: A neurotrophic and neuroprotective metabolite of docosahexaenoic acid

Kim, H., & Spector, A. A. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.03.004 · Cited by 112 · see citing works

Phenotypic and genetic spectrum of <i><scp>SCN</scp>8A</i>‐related disorders, treatment options, and outcomes

Gardella, E., & Møller, R. S. (2019) · Epilepsia · doi:10.1111/epi.16319 · Cited by 104 · see citing works

NBI-921352, a first-in-class, NaV1.6 selective, sodium channel inhibitor that prevents seizures in Scn8a gain-of-function mice, and wild-type mice and rats

Johnson, J., Focken, T., Khakh, K., Tari, P. K., Dube, C., Williams, A., Andrez, J.-C., Bankar, G., Bogucki, D., Burford, K., et al. (2022) · eLife · doi:10.7554/elife.72468 · Cited by 80 · see citing works

Design and Mechanism of (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic Acid, a Highly Potent γ-Aminobutyric Acid Aminotransferase Inactivator for the Treatment of Addiction

Juncosa, J. I., Takaya, K., Le, H. V., Moschitto, M. J., Weerawarna, P. M., Mascarenhas, R., Liu, D., Dewey, S. L., & Silverman, R. B. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b10965 · Cited by 71 · see citing works

The ups and downs of alkyl‐carbamates in epilepsy therapy: How does cenobamate differ?

Löscher, W., Sills, G. J., & White, H. S. (2021) · Epilepsia · doi:10.1111/epi.16832 · Cited by 71 · see citing works

Visual Field Loss in Patients with Refractory Partial Epilepsy Treated with Vigabatrin

Wild, J. M., Chiron, C., Ahn, H., Baulac, M., Bursztyn, J., Gandolfo, E., Goldberg, I., Goñi, F. J., Mercier, F., Nordmann, J., et al. (2009) · CNS Drugs · doi:10.2165/11317650-000000000-00000 · Cited by 70 · see citing works

Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development

Bialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2018) · Epilepsia · doi:10.1111/epi.14555 · Cited by 53 · see citing works

Targeting the 18-kDa translocator protein: recent perspectives for neuroprotection

Pozzo, E. D., Giacomelli, C., Barresi, E., Costa, B., Taliani, S., Settimo, F. D., & Martini, C. (2015) · Biochemical Society Transactions · doi:10.1042/bst20150028 · Cited by 41 · see citing works

Retigabine as adjunctive therapy in adults with partial-onset seizures: Integrated analysis of three pivotal controlled trials

Porter, R. J., Burdette, D. E., Gil‐Nagel, A., Hall, S. T., White, R., Shaikh, S., & DeRossett, S. E. (2012) · Epilepsy Research · doi:10.1016/j.eplepsyres.2012.03.010 · Cited by 38 · see citing works

Clinical Pharmacokinetics of Retigabine/Ezogabine

Tompson, D. J., & Crean, C. S. (2013) · Current Clinical Pharmacology · doi:10.2174/15748847113089990053 · Cited by 27 · see citing works

n−3 polyunsaturated N-acylethanolamines are CB2 cannabinoid receptor-preferring endocannabinoids

Alharthi, N. S., Christensen, P. S., Hourani, W., Ortori, C. A., Barrett, D. A., Bennett, A. J., Chapman, V., & Alexander, S. P. H. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.08.003 · Cited by 26 · see citing works

The Translocator Protein 18 kDa (TSPO) and Its Role in Mitochondrial Biology and Psychiatric Disorders

Milenkovic, V. M., Rupprecht, R., & Wetzel, C. H. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666150324122642 · Cited by 23 · see citing works

OV329, a novel highly potent γ‐aminobutyric acid aminotransferase inactivator, induces pronounced anticonvulsant effects in the pentylenetetrazole seizure threshold test and in amygdala‐kindled rats

Feja, M., Meller, S., Deking, L. S., Kaczmarek, E., During, M. J., Silverman, R. B., & Gernert, M. (2021) · Epilepsia · doi:10.1111/epi.17090 · Cited by 22 · see citing works

The novel dual-mechanism Kv7 potassium channel/TSPO receptor activator GRT-X is more effective than the Kv7 channel opener retigabine in the 6-Hz refractory seizure mouse model

Bloms-Funke, P., Bankstahl, M., Bankstahl, J., Kneip, C., Schröder, W., & Löscher, W. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108884 · Cited by 19 · see citing works

A novel dual mode-of-action anti-hyperalgesic compound in rats which is neuroprotective and promotes neuroregeneration

Bloms‐Funke, P., Schumacher, M., Liu, S., Su, D., Li, J., Lière, P., Rupprecht, R., Nothdurfter, C., Bahrenberg, G., Christoph, T., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174935 · Cited by 12 · see citing works

The Interaction Potential of Retigabine (Ezogabine) with Other Antiepileptic Drugs

Tompson, D. J., & Crean, C. S. (2014) · Current Clinical Pharmacology · doi:10.2174/1574884708666131111192311 · Cited by 10 · see citing works

Cannabinoid Receptor Modulation of Neurogenesis: ST14A Striatal Neural Progenitor Cells as a Simplified In Vitro Model

Cottone, E., Pomatto, V., Rapelli, S., Scandiffio, R., Mackie, K., & Bovolin, P. (2021) · Molecules · doi:10.3390/molecules26051448 · Cited by 7 · see citing works

Pharmacokinetic and Food Effect Assessment of XEN496 (Pediatric Formulation of Ezogabine) in Healthy Adults and Relative Bioavailability Assessment with Potiga® (Adult Formulation of Ezogabine) (4918)

Cadieux, J. A., Namdari, R., Beatch, G. N., & Aycardi, E. (2020) · Neurology · doi:10.1212/wnl.94.15_supplement.4918 · Cited by 1 · see citing works

Drug resistance in epilepsy

Perucca, E., Perucca, P., White, H. S., & Wirrell, E. C. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00151-5 · Cited by 342 · see citing works

Developmental and epileptic encephalopathies

Scheffer, I. E., Zuberi, S., Mefford, H. C., Guerrini, R., & McTague, A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00546-6 · Cited by 128 · see citing works

Pharmacological aspects of antiseizure medications: From basic mechanisms to clinical considerations of drug interactions and use of therapeutic drug monitoring

Landmark, C. J., Eyal, S., Burns, M. L., Franco, V., & Johannessen, S. I. (2023) · Epileptic Disorders · doi:10.1002/epd2.20069 · Cited by 68 · see citing works

Advances in Epilepsy: Mechanisms, Clinical Trials, and Drug Therapies

Hu, T., Zhang, J., Wang, J., Sha, L., Xia, Y., Ortyl, T. C., Tian, X., & Chen, L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01975 · Cited by 55 · see citing works

Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development

Bialer, M., Johannessen, S. I., Koepp, M. J., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2024) · Epilepsia · doi:10.1111/epi.18056 · Cited by 32 · see citing works

Nose-to-brain delivery of perampanel formulated in a self-microemulsifying drug delivery system improves anticonvulsant and anxiolytic activity in mice

Meirinho, S., Rodrigues, M., Santos, A. O., Falcão, A. C., & Alves, G. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123145 · Cited by 15 · see citing works

In silico screening for clinical efficacy of antiseizure medications: Not all central nervous system drugs are alike

Hamed, R., Eyal, A. D., Berman, E., & Eyal, S. (2022) · Epilepsia · doi:10.1111/epi.17479 · Cited by 13 · see citing works

Voltage-gated sodium channels in the nervous system: Molecular physiology to therapeutic interventions

Li, N., Yan, L., Peng, A., Fu, X., Qin, H., & Yao, K. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00260 · Cited by 6 · see citing works

Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades

Bialer, M., & Perucca, E. (2026) · Drugs · doi:10.1007/s40265-026-02297-y · Cited by 3 · see citing works

Effects of Small Conductance Ca 2+ ‐Activated Potassium Channel Agonists on SLEs in Varied Epilepsy Models, From Animal Slices to Pharmacoresistant Human Tissue

Raza, M. L., Haq, R. U., & Heinemann, U. (2025) · Journal of Neuroscience Research · doi:10.1002/jnr.70078 · Cited by 2 · see citing works

Imperatorin interacts additively with novel antiseizure medications in the mouse maximal electroshock-induced seizure model: an isobolographic transformation

Łuszczki, J. J., Kochman, E., Bojar, H., Florek-Łuszczki, M., & Skalicka‐Woźniak, K. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00555-4 · Cited by 1 · see citing works

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices ( EILAT XVIII ). II . Treatments in more advanced clinical development

Bialer, M., Landmark, C. J., Koepp, M. J., Perucca, E., Perucca, P., Tomson, T., White, H. S., & Wirrell, E. C. (2026) · Epilepsia · doi:10.1002/epi.70346 · Cited by 1 · see citing works

Pharmacokinetic Variability of Rufinamide and Stiripentol in Children With Refractory Epilepsy: A Retrospective Study of Therapeutic Drug Monitoring From the National Epilepsy Centers in Denmark and Norway

Heger, K., Burns, M. L., Nikanorova, M., Johannessen, S. I., & Landmark, C. J. (2024) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001219 · Cited by 1 · see citing works

Knowledge about the Management of Anti-Epileptic Drug Treatment among General Practitioners in Brazzaville, Congo

Diatewa, J. E., Mondzié, I. F. N., Motoula-Latou, D. H. B., Sounga-Banzouzi, E. P. G., Kaba, Y., Mpandzou, G. A., & Ossou-Nguıet, P. M. (2023) · Neuroscience &amp Medicine · doi:10.4236/nm.2023.142002 · Cited by 1 · see citing works

Antiepileptic drugs

Vardanyan, R., & Vardanyan, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33869-4.00005-3

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices ( EILAT XVIII ). I. Treatments in preclinical and early clinical development

Bialer, M., Landmark, C. J., Koepp, M. J., Perucca, E., Perucca, P., Tomson, T., White, H. S., & Wirrell, E. C. (2026) · Epilepsia · doi:10.1002/epi.70354

BindingDB Entry 50020695: Advances in Epilepsy: Mechanisms, Clinical Trials, and Drug Therapies.

BindingDB (2024) · UC San Diego · doi:10.7270/q2sq94v8

GAO-3-02

Belmeguenaï, A., Bodennec, S., Bezin, L., Guyon, J., & Bodennec, J. (2022) · HAL

Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in preclinical and early clinical development

Bialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2020) · Epilepsia · doi:10.1111/epi.16725 · Cited by 149 · see citing works

Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices ( EILAT XVI ): II . Drugs in more advanced clinical development

Bialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2022) · Epilepsia · doi:10.1111/epi.17376 · Cited by 34 · see citing works

Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development

Bialer, M., Johannessen, S. I., Koepp, M. J., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2024) · Epilepsia · doi:10.1111/epi.18056 · Cited by 32 · see citing works

Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development

Bialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Tomson, T., & White, H. S. (2018) · Epilepsia · doi:10.1111/epi.14557 · Cited by 130 · see citing works